1. Home
  2. CTSO vs LOAN Comparison

CTSO vs LOAN Comparison

Compare CTSO & LOAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTSO
  • LOAN
  • Stock Information
  • Founded
  • CTSO 1997
  • LOAN 1989
  • Country
  • CTSO United States
  • LOAN United States
  • Employees
  • CTSO N/A
  • LOAN N/A
  • Industry
  • CTSO Medical/Dental Instruments
  • LOAN Real Estate Investment Trusts
  • Sector
  • CTSO Health Care
  • LOAN Real Estate
  • Exchange
  • CTSO Nasdaq
  • LOAN Nasdaq
  • Market Cap
  • CTSO 61.7M
  • LOAN 61.5M
  • IPO Year
  • CTSO N/A
  • LOAN 1999
  • Fundamental
  • Price
  • CTSO $1.00
  • LOAN $5.38
  • Analyst Decision
  • CTSO Buy
  • LOAN
  • Analyst Count
  • CTSO 2
  • LOAN 0
  • Target Price
  • CTSO $5.50
  • LOAN N/A
  • AVG Volume (30 Days)
  • CTSO 123.9K
  • LOAN 24.1K
  • Earning Date
  • CTSO 11-06-2025
  • LOAN 10-22-2025
  • Dividend Yield
  • CTSO N/A
  • LOAN 8.52%
  • EPS Growth
  • CTSO N/A
  • LOAN N/A
  • EPS
  • CTSO N/A
  • LOAN 0.48
  • Revenue
  • CTSO $36,107,520.00
  • LOAN $7,300,469.00
  • Revenue This Year
  • CTSO $11.93
  • LOAN N/A
  • Revenue Next Year
  • CTSO $21.22
  • LOAN $4.47
  • P/E Ratio
  • CTSO N/A
  • LOAN $11.25
  • Revenue Growth
  • CTSO 20.18
  • LOAN N/A
  • 52 Week Low
  • CTSO $0.71
  • LOAN $4.74
  • 52 Week High
  • CTSO $1.61
  • LOAN $6.05
  • Technical
  • Relative Strength Index (RSI)
  • CTSO 52.14
  • LOAN 49.05
  • Support Level
  • CTSO $0.94
  • LOAN $5.32
  • Resistance Level
  • CTSO $0.99
  • LOAN $5.44
  • Average True Range (ATR)
  • CTSO 0.07
  • LOAN 0.11
  • MACD
  • CTSO 0.01
  • LOAN 0.00
  • Stochastic Oscillator
  • CTSO 82.21
  • LOAN 66.67

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

Share on Social Networks: